世界の抗肥満薬市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)

GlobalInfoResearchが発行した調査報告書(GIR21JY00001)
◆英語タイトル:Global Anti-obesity Medicine Market 2021 by Company, Regions, Type and Application, Forecast to 2026
◆商品コード:GIR21JY00001
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2021年7月(※2024年版があります。お問い合わせください。)
◆ページ数:91
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2~3日)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

GlobalInfoResearch社の本調査レポートでは、抗肥満薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。抗肥満薬の種類別市場規模(処方薬、OTC薬)、用途別市場規模(男性、女性)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・メーカー情報(企業概要、製品概要、販売量、価格、売上):Alizyme、Amylin Pharmaceuticals、Arena Pharmaceuticals、Boehringer Ingelheim、Eisai、GlaxoSmithKline、Orexigen Therapeutics、Vivus、Pfizer、Roche、Merck、Novo Nordisk
・メーカー別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:処方薬、OTC薬
・用途別分析2016年-2026年:男性、女性
・抗肥満薬の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・抗肥満薬のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・抗肥満薬のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・抗肥満薬の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・抗肥満薬の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
【レポートの概要】

The Anti-obesity Medicine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Anti-obesity Medicine size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Anti-obesity Medicine market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Anti-obesity Medicine market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Prescription Drugs
OTC Drugs

Market segment by Application, can be divided into
Men
Women

Market segment by players, this report covers
Alizyme
Amylin Pharmaceuticals
Arena Pharmaceuticals
Boehringer Ingelheim
Eisai
GlaxoSmithKline
Orexigen Therapeutics
Vivus
Pfizer
Roche
Merck
Novo Nordisk

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Anti-obesity Medicine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Anti-obesity Medicine, with revenue, gross margin and global market share of Anti-obesity Medicine from 2019 to 2021.
Chapter 3, the Anti-obesity Medicine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Anti-obesity Medicine market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Anti-obesity Medicine research findings and conclusion, appendix and data source.

【レポートの目次】

1 Market Overview
1.1 Product Overview and Scope of Anti-obesity Medicine
1.2 Classification of Anti-obesity Medicine by Type
1.2.1 Overview: Global Anti-obesity Medicine Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Anti-obesity Medicine Revenue Market Share by Type in 2020
1.2.3 Prescription Drugs
1.2.4 OTC Drugs
1.3 Global Anti-obesity Medicine Market by Application
1.3.1 Overview: Global Anti-obesity Medicine Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Men
1.3.3 Women
1.4 Global Anti-obesity Medicine Market Size & Forecast
1.5 Global Anti-obesity Medicine Market Size and Forecast by Region
1.5.1 Global Anti-obesity Medicine Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Anti-obesity Medicine Market Size by Region, (2016-2021)
1.5.3 North America Anti-obesity Medicine Market Size and Prospect (2016-2026)
1.5.4 Europe Anti-obesity Medicine Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Anti-obesity Medicine Market Size and Prospect (2016-2026)
1.5.6 South America Anti-obesity Medicine Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Anti-obesity Medicine Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Anti-obesity Medicine Market Drivers
1.6.2 Anti-obesity Medicine Market Restraints
1.6.3 Anti-obesity Medicine Trends Analysis
2 Company Profiles
2.1 Alizyme
2.1.1 Alizyme Details
2.1.2 Alizyme Major Business
2.1.3 Alizyme Anti-obesity Medicine Product and Solutions
2.1.4 Alizyme Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Alizyme Recent Developments and Future Plans
2.2 Amylin Pharmaceuticals
2.2.1 Amylin Pharmaceuticals Details
2.2.2 Amylin Pharmaceuticals Major Business
2.2.3 Amylin Pharmaceuticals Anti-obesity Medicine Product and Solutions
2.2.4 Amylin Pharmaceuticals Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Amylin Pharmaceuticals Recent Developments and Future Plans
2.3 Arena Pharmaceuticals
2.3.1 Arena Pharmaceuticals Details
2.3.2 Arena Pharmaceuticals Major Business
2.3.3 Arena Pharmaceuticals Anti-obesity Medicine Product and Solutions
2.3.4 Arena Pharmaceuticals Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Arena Pharmaceuticals Recent Developments and Future Plans
2.4 Boehringer Ingelheim
2.4.1 Boehringer Ingelheim Details
2.4.2 Boehringer Ingelheim Major Business
2.4.3 Boehringer Ingelheim Anti-obesity Medicine Product and Solutions
2.4.4 Boehringer Ingelheim Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Boehringer Ingelheim Recent Developments and Future Plans
2.5 Eisai
2.5.1 Eisai Details
2.5.2 Eisai Major Business
2.5.3 Eisai Anti-obesity Medicine Product and Solutions
2.5.4 Eisai Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Eisai Recent Developments and Future Plans
2.6 GlaxoSmithKline
2.6.1 GlaxoSmithKline Details
2.6.2 GlaxoSmithKline Major Business
2.6.3 GlaxoSmithKline Anti-obesity Medicine Product and Solutions
2.6.4 GlaxoSmithKline Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 GlaxoSmithKline Recent Developments and Future Plans
2.7 Orexigen Therapeutics
2.7.1 Orexigen Therapeutics Details
2.7.2 Orexigen Therapeutics Major Business
2.7.3 Orexigen Therapeutics Anti-obesity Medicine Product and Solutions
2.7.4 Orexigen Therapeutics Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Orexigen Therapeutics Recent Developments and Future Plans
2.8 Vivus
2.8.1 Vivus Details
2.8.2 Vivus Major Business
2.8.3 Vivus Anti-obesity Medicine Product and Solutions
2.8.4 Vivus Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Vivus Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Anti-obesity Medicine Product and Solutions
2.9.4 Pfizer Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Pfizer Recent Developments and Future Plans
2.10 Roche
2.10.1 Roche Details
2.10.2 Roche Major Business
2.10.3 Roche Anti-obesity Medicine Product and Solutions
2.10.4 Roche Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Roche Recent Developments and Future Plans
2.11 Merck
2.11.1 Merck Details
2.11.2 Merck Major Business
2.11.3 Merck Anti-obesity Medicine Product and Solutions
2.11.4 Merck Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Merck Recent Developments and Future Plans
2.12 Novo Nordisk
2.12.1 Novo Nordisk Details
2.12.2 Novo Nordisk Major Business
2.12.3 Novo Nordisk Anti-obesity Medicine Product and Solutions
2.12.4 Novo Nordisk Anti-obesity Medicine Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Novo Nordisk Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Anti-obesity Medicine Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Anti-obesity Medicine Players Market Share
3.2.2 Top 10 Anti-obesity Medicine Players Market Share
3.2.3 Market Competition Trend
3.3 Anti-obesity Medicine Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Anti-obesity Medicine Revenue and Market Share by Type (2016-2021)
4.2 Global Anti-obesity Medicine Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Anti-obesity Medicine Revenue Market Share by Application (2016-2021)
5.2 Anti-obesity Medicine Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Anti-obesity Medicine Revenue by Type (2016-2026)
6.2 North America Anti-obesity Medicine Revenue by Application (2016-2026)
6.3 North America Anti-obesity Medicine Market Size by Country
6.3.1 North America Anti-obesity Medicine Revenue by Country (2016-2026)
6.3.2 United States Anti-obesity Medicine Market Size and Forecast (2016-2026)
6.3.3 Canada Anti-obesity Medicine Market Size and Forecast (2016-2026)
6.3.4 Mexico Anti-obesity Medicine Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Anti-obesity Medicine Revenue by Type (2016-2026)
7.2 Europe Anti-obesity Medicine Revenue by Application (2016-2026)
7.3 Europe Anti-obesity Medicine Market Size by Country
7.3.1 Europe Anti-obesity Medicine Revenue by Country (2016-2026)
7.3.2 Germany Anti-obesity Medicine Market Size and Forecast (2016-2026)
7.3.3 France Anti-obesity Medicine Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Anti-obesity Medicine Market Size and Forecast (2016-2026)
7.3.5 Russia Anti-obesity Medicine Market Size and Forecast (2016-2026)
7.3.6 Italy Anti-obesity Medicine Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Anti-obesity Medicine Revenue by Type (2016-2026)
8.2 Asia-Pacific Anti-obesity Medicine Revenue by Application (2016-2026)
8.3 Asia-Pacific Anti-obesity Medicine Market Size by Region
8.3.1 Asia-Pacific Anti-obesity Medicine Revenue by Region (2016-2026)
8.3.2 China Anti-obesity Medicine Market Size and Forecast (2016-2026)
8.3.3 Japan Anti-obesity Medicine Market Size and Forecast (2016-2026)
8.3.4 South Korea Anti-obesity Medicine Market Size and Forecast (2016-2026)
8.3.5 India Anti-obesity Medicine Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Anti-obesity Medicine Market Size and Forecast (2016-2026)
8.3.7 Australia Anti-obesity Medicine Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Anti-obesity Medicine Revenue by Type (2016-2026)
9.2 South America Anti-obesity Medicine Revenue by Application (2016-2026)
9.3 South America Anti-obesity Medicine Market Size by Country
9.3.1 South America Anti-obesity Medicine Revenue by Country (2016-2026)
9.3.2 Brazil Anti-obesity Medicine Market Size and Forecast (2016-2026)
9.3.3 Argentina Anti-obesity Medicine Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Anti-obesity Medicine Revenue by Type (2016-2026)
10.2 Middle East & Africa Anti-obesity Medicine Revenue by Application (2016-2026)
10.3 Middle East & Africa Anti-obesity Medicine Market Size by Country
10.3.1 Middle East & Africa Anti-obesity Medicine Revenue by Country (2016-2026)
10.3.2 Turkey Anti-obesity Medicine Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Anti-obesity Medicine Market Size and Forecast (2016-2026)
10.3.4 UAE Anti-obesity Medicine Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

...

【掲載企業】

Alizyme、Amylin Pharmaceuticals、Arena Pharmaceuticals、Boehringer Ingelheim、Eisai、GlaxoSmithKline、Orexigen Therapeutics、Vivus、Pfizer、Roche、Merck、Novo Nordisk

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の抗肥満薬市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)(Global Anti-obesity Medicine Market 2021 by Company, Regions, Type and Application, Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。